These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 22737400)
1. Clickable, photoreactive inhibitors to probe the active site microenvironment of fatty acid amide hydrolase(). Saario SM; McKinney MK; Speers AE; Wang C; Cravatt BF Chem Sci; 2012 Jan; 3(1):77-83. PubMed ID: 22737400 [TBL] [Abstract][Full Text] [Related]
2. Characterization and manipulation of the acyl chain selectivity of fatty acid amide hydrolase. Patricelli MP; Cravatt BF Biochemistry; 2001 May; 40(20):6107-15. PubMed ID: 11352748 [TBL] [Abstract][Full Text] [Related]
3. A Personal Retrospective: Elevating Anandamide (AEA) by Targeting Fatty Acid Amide Hydrolase (FAAH) and the Fatty Acid Binding Proteins (FABPs). Deutsch DG Front Pharmacol; 2016; 7():370. PubMed ID: 27790143 [TBL] [Abstract][Full Text] [Related]
4. Characterization of a Fatty Acid Amide Hydrolase (FAAH) in Hirudo Verbana. Kabeiseman E; Paulsen RT; Burrell BD Neurochem Res; 2024 Aug; ():. PubMed ID: 39093361 [TBL] [Abstract][Full Text] [Related]
5. Endocannabinoid metabolism in the absence of fatty acid amide hydrolase (FAAH): discovery of phosphorylcholine derivatives of N-acyl ethanolamines. Mulder AM; Cravatt BF Biochemistry; 2006 Sep; 45(38):11267-77. PubMed ID: 16981687 [TBL] [Abstract][Full Text] [Related]
6. Discovery and molecular basis of potent noncovalent inhibitors of fatty acid amide hydrolase (FAAH). Min X; Thibault ST; Porter AC; Gustin DJ; Carlson TJ; Xu H; Lindstrom M; Xu G; Uyeda C; Ma Z; Li Y; Kayser F; Walker NP; Wang Z Proc Natl Acad Sci U S A; 2011 May; 108(18):7379-84. PubMed ID: 21502526 [TBL] [Abstract][Full Text] [Related]
7. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. Guindon J; Lai Y; Takacs SM; Bradshaw HB; Hohmann AG Pharmacol Res; 2013 Jan; 67(1):94-109. PubMed ID: 23127915 [TBL] [Abstract][Full Text] [Related]
8. Membrane lipids are key modulators of the endocannabinoid-hydrolase FAAH. Dainese E; De Fabritiis G; Sabatucci A; Oddi S; Angelucci CB; Di Pancrazio C; Giorgino T; Stanley N; Del Carlo M; Cravatt BF; Maccarrone M Biochem J; 2014 Feb; 457(3):463-72. PubMed ID: 24215562 [TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors. Dickason-Chesterfield AK; Kidd SR; Moore SA; Schaus JM; Liu B; Nomikos GG; Felder CC Cell Mol Neurobiol; 2006; 26(4-6):407-23. PubMed ID: 16736384 [TBL] [Abstract][Full Text] [Related]
10. Biochemical characterization and in vitro activity of AZ513, a noncovalent, reversible, and noncompetitive inhibitor of fatty acid amide hydrolase. Scott CW; Tian G; Yu XH; Paschetto KA; Wilkins DE; Meury L; Cao CQ; Varnes J; Edwards PD Eur J Pharmacol; 2011 Sep; 667(1-3):74-9. PubMed ID: 21645511 [TBL] [Abstract][Full Text] [Related]
11. Anandamide uptake is consistent with rate-limited diffusion and is regulated by the degree of its hydrolysis by fatty acid amide hydrolase. Kaczocha M; Hermann A; Glaser ST; Bojesen IN; Deutsch DG J Biol Chem; 2006 Apr; 281(14):9066-75. PubMed ID: 16461355 [TBL] [Abstract][Full Text] [Related]
12. O-hydroxyacetamide carbamates as a highly potent and selective class of endocannabinoid hydrolase inhibitors. Niphakis MJ; Johnson DS; Ballard TE; Stiff C; Cravatt BF ACS Chem Neurosci; 2012 May; 3(5):418-26. PubMed ID: 22860211 [TBL] [Abstract][Full Text] [Related]
13. Keys to Lipid Selection in Fatty Acid Amide Hydrolase Catalysis: Structural Flexibility, Gating Residues and Multiple Binding Pockets. Palermo G; Bauer I; Campomanes P; Cavalli A; Armirotti A; Girotto S; Rothlisberger U; De Vivo M PLoS Comput Biol; 2015 Jun; 11(6):e1004231. PubMed ID: 26111155 [TBL] [Abstract][Full Text] [Related]